法治在线丨处方药遭非法倒卖 起底医保“回流药”黑色产业链

Core Viewpoint - The illegal resale of medical insurance drugs, known as "medical insurance return drugs," poses significant health risks to users and severely undermines the security of the national medical insurance fund [1]. Group 1: Illegal Activities and Law Enforcement - In Jiangxi Jingdezhen, police seized over 10,000 boxes of medical insurance return drugs from a residential property [3][5]. - The drugs, primarily prescription medications for dialysis treatment, were found stored improperly in a residential setting, raising concerns about their safety and legality [6][11]. - The main suspect, Dai Mingshou, was previously under criminal supervision for similar offenses but continued to engage in illegal drug sales [9][18]. Group 2: Drug Sourcing and Market Dynamics - The drugs were sourced from patients and intermediaries, with a network of "second-hand dealers" facilitating the illegal trade [18][22]. - Dai Mingshou purchased drugs at prices ranging from 170 to 180 yuan and resold them for 185 to 200 yuan, exploiting the medical insurance system to profit from the low out-of-pocket costs for patients [20][22]. - The illegal operation involved using coded language for communication to evade law enforcement, indicating a sophisticated network of drug trafficking [23][25]. Group 3: Legal Consequences and Judicial Actions - The total value of the drugs involved in the case exceeded 13 million yuan, with multiple individuals in the supply chain facing legal repercussions [30][33]. - Dai Mingshou was sentenced to six years in prison and fined 120,000 yuan for concealing and disguising criminal proceeds, highlighting the judicial system's response to such crimes [37][39]. - The case underscores the broader issue of medical insurance fraud and its detrimental impact on public health and the integrity of the medical insurance fund [31][39]. Group 4: Regulatory Measures and Public Awareness - The National Medical Insurance Bureau, in collaboration with various authorities, has initiated a nationwide crackdown on issues related to medical insurance fund management, focusing on the illegal sale of return drugs [41]. - The introduction of a drug traceability feature in the National Medical Insurance Service Platform App allows consumers to verify the legitimacy of medications, promoting public awareness and safety [43].